Stay updated with breaking news from Orphan receptor. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Data and Safety Monitoring Board Approves Simultaneous Enrollment in Cohort 3 and Phase 2 Initiation in OCU410 ArMaDa study for Geographic Atrophy marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.
Research analysts at StockNews.com initiated coverage on shares of Oncternal Therapeutics (NASDAQ:ONCT – Get Free Report) in a research report issued to clients and investors on Monday. The brokerage set a “hold” rating on the stock. Separately, HC Wainwright dropped their target price on shares of Oncternal Therapeutics from $28.00 to $19.00 and set a […] ....
StockNews.com began coverage on shares of Oncternal Therapeutics (NASDAQ:ONCT – Free Report) in a research note published on Sunday morning. The firm issued a hold rating on the stock. Separately, HC Wainwright reduced their price objective on Oncternal Therapeutics from $28.00 to $19.00 and set a buy rating on the stock in a research note […] ....
Ocugen Announces Dosing Completion of Subjects with Stargardt Disease in Cohort 2 of Phase 1/2 GARDian Clinical Trial of OCU410ST—A Modifier Gene Therapy marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.
Ocugen (OCGN) Completes Dosing of Subjects with Stargardt Disease in Cohort 2 of Phase 1/2 GARDian Trial of OCU410ST streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.